Neuroendocrine Carcinoma clinical trials at UCLA
2 in progress, 1 open to eligible people
Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
open to eligible people ages 12 years and up
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Los Angeles, California and other locations
Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Sorry, in progress, not accepting new patients
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
Los Angeles, California and other locations
Our lead scientists for Neuroendocrine Carcinoma research studies include Jonathan Goldman.
Last updated: